Prometheus Biosciences

Investors fund Prometheus team's 'unfinished business' with $400M for new inflammatory biotech Mirador
Fierce Biotech
Thu, 03/21/24 - 11:27 am
Prometheus Biosciences
funding
Mirador
Merck still in the market for deals in the $1B to $15B range, CEO says
Fierce Pharma
Thu, 02/1/24 - 10:56 pm
Merck
M&A
Pharma CEOs
Rob Davis
Prometheus Biosciences
Merck still scouting for M&A deals, even after $10.8B takeover of Prometheus
Fierce Pharma
Tue, 08/1/23 - 10:19 pm
Merck
Prometheus Biosciences
M&A
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Tue, 06/13/23 - 11:37 am
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Heightened US antitrust fears rattle biopharma
EP Vantage
Wed, 05/17/23 - 10:12 am
M&A
antitrust
Amgen
Astellas
Bellus Health
Globus Medical
GSK
Horizon Therapeutics
Merck
NuVasive
Pfizer
Prometheus Biosciences
Seagen
Merck bets big on PRA023 with $10.8bn Prometheus acquisition offer
Clinical Trials Arena
Wed, 05/3/23 - 10:37 pm
Merck
Prometheus Biosciences
PRA023
ulcerative colitis
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
Crain's Chicago Business
Mon, 05/1/23 - 10:15 pm
Merck
Prometheus Biosciences
M&A
AbbVie
Bristol Myers Squibb
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Fierce Pharma
Tue, 04/18/23 - 10:10 pm
Big Pharma
M&A
Merck
Prometheus Biosciences
GSK
Bellus Health
Merck’s latest deal turns up the spotlight on immune system drugmakers
BioPharma Dive
Mon, 04/17/23 - 10:47 pm
Merck
M&A
Prometheus Biosciences
immunology
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
BioPharma Dive
Sun, 04/16/23 - 11:31 pm
Merck
M&A
Prometheus Biosciences
IBD
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Prometheus Biosciences Catapults 176% On Promising Results In UC and Crohn's
Investors Business Daily
Wed, 12/7/22 - 09:40 am
Prometheus Biosciences
clinical trials
ulcerative colitis
Crohn’s disease
Pfizer hands another asset to Roivant
EP Vantage
Fri, 12/2/22 - 10:56 am
Pfizer
Roivant
RVT-3101
PF-06480605
Prometheus Biosciences
Can This Tiny Biotech Take On Pfizer?
Motley Fool
Tue, 09/20/22 - 10:19 am
Prometheus Biosciences
Pfizer
inflammatory bowel disease
PRA023
Prometheus takes on Pfizer in inflammatory bowel diseases
EP Vantage
Fri, 09/16/22 - 10:11 am
Prometheus Biosciences
Pfizer
PF-06480605
PRA023
inflammatory bowel disease
Prometheus upsizes IPO by 33% ahead of pricing
Endpoints
Thu, 03/11/21 - 11:43 pm
Prometheus Biosciences
IPOs
After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard
Endpoints
Mon, 02/22/21 - 11:45 pm
IPOs
Prometheus Biosciences
Longboard Pharmaceuticals
Gain Therapeutics